The Federal Circuit remanded an appeal by Xencor, giving the USPTO a chance to revisit the written description requirement for antibody patents. This case highlights the continuously evolving standards for written descriptions requirements in biotech patenting. The case presents important policy considerations for how much scope a patentee can obtain based on the explicit teachings within a specification.
